Suven Pharma's Q4 Financial Results Show Significant Decline in Profits and Sales

Suven Pharmaceuticals, a midcap company in the pharma industry, recently declared its financial results for the quarter ending March 2024. According to the latest report, the company has seen a very negative performance in terms of financials, with a score of -20 compared to -18 in the previous quarter.

One of the major factors contributing to this decline is the Profit Before Tax (PBT) less Other Income, which has fallen by 51.6% to Rs 53.80 crore from the average PBT of the previous four quarters, which was Rs 111.20 crore. This trend is expected to continue in the near term.

Similarly, the Profit After Tax (PAT) has also seen a significant decline of 42.4% to Rs 53.37 crore from the average PAT of the previous four quarters, which was Rs 92.72 crore. This is another major concern for the company in the near term.

In terms of sales, Suven Pharma has reported a decline of 13.4% in its quarterly net sales, which stands at Rs 252.93 crore compared to the average net sales of the previous four quarters, which was Rs 291.95 crore. This indicates a very negative trend in the company's sales performance.

Based on these financial results, MarketsMOJO has given a 'Sell' call for Suven Pharma's stock. The company needs to address these issues and take necessary steps to improve its financial performance in the future.